Our Partners

• MHLW-licensed under the Act on the Safety of Regenerative Medicine.Each protocol is filed with Japan's Ministry of Health, Labour and Welfare under the 2014 regenerative-medicine framework, with mandatory adverse-event reporting as a condition of licence.

• Safety published in a peer-reviewed journal.A 2024 paper in Stem Cells Translational Medicine tracked 2,500+ patients receiving IV stem-cell therapy at Helene. Result: 0% severe adverse events.

• Pharmaceutical-grade manufacturing.The cell-processing centre operates to GMP-compliant standards under an ISO 9001:2015 quality management system — the international benchmark for medical-grade production.

• ISO Class 5 cleanroom processing.Cells are cultivated under the international classification used in pharmaceutical biologics manufacturing — the strictest practical environmental standard for cell production.

• PIC/S GMP-aligned manufacturing.Built to the Pharmaceutical Inspection Co-operation Scheme standard — the global mutual-recognition framework for pharmaceutical manufacturing quality.

• Their own cell-growth medium."HELENE Medium" is animal-serum-free, GMP-grade, and developed in-house — used since the clinic opened.

• Five-year cultivated cell-line preservation.Once cultivated, your personal cell line is cryopreserved and available for repeat infusions over a five-year window — distinguishing autologous protocols from one-shot treatments.

• A decade of clinical operation in Tokyo.Helene has been treating patients in Minami-Aoyama for over ten years — a meaningful track record in a field where most clinics are under five.

Helene Clinic's treatments filed and licensed under Japan's Act on the Safety of Regenerative Medicine for the following conditions:

• Type 1 & Type 2 diabetes — metabolic regulation and insulin sensitivity
• Osteoarthritis — knee and joint pain from cartilage wear
• Neurodegenerative diseases — Alzheimer's and Parkinson's protocols
• Dental diseases — periodontal regeneration and oral tissue repair
• Cardiovascular disease — major adverse cardiovascular events (MACCE)
• Stroke recovery — post-cerebral-infarction rehabilitation
• Immune system frailty — resilience and immune balance
• Hair loss (alopecia) — follicle regeneration and scalp protocols
• Facial rejuvenation — skin renewal and biological-age signalling
• Female hormone imbalance — endocrine support
• Erectile dysfunction — vascular and tissue regeneration

A licensed treatment plan is not a guaranteed cure. Outcomes vary, benefits may be partial or gradual, and suitability for each protocol is determined during specialist consultation.

Starting from JPY 1,450,000 (≈ SGD 11,800) for 100 million stem cells. Pricing scales with the cell count agreed with your physician.

• JPY 1,000,000 deposit during stem-cell collection
• Balance paid at infusion

The figure above is indicative for the baseline 100-million-cell tier. Higher cell-count protocols may be clinically advised for systemic conditions and are priced proportionally.

Starting from MYR 59,000 (≈ SGD 17,000) for the baseline allogeneic protocol — a single-day, all-in-one procedure.

• Same-day delivery — screening, consultation, and infusion completed in one visit
• Payment made directly to the clinic on the day of treatment

Final pricing scales with the cell count agreed with your physician. The figure above is indicative for the baseline tier; higher cell-count protocols may be clinically advised for systemic conditions and are priced proportionally.